CY1105566T1 - Ποσοτικη διαγνωστικη αναλυση της προδιαθεσης για υπερταση - Google Patents

Ποσοτικη διαγνωστικη αναλυση της προδιαθεσης για υπερταση

Info

Publication number
CY1105566T1
CY1105566T1 CY20061101052T CY061101052T CY1105566T1 CY 1105566 T1 CY1105566 T1 CY 1105566T1 CY 20061101052 T CY20061101052 T CY 20061101052T CY 061101052 T CY061101052 T CY 061101052T CY 1105566 T1 CY1105566 T1 CY 1105566T1
Authority
CY
Cyprus
Prior art keywords
hypertension
predisposition
relates
detection
diagnostic analysis
Prior art date
Application number
CY20061101052T
Other languages
English (en)
Inventor
Florian Lang
Andreas Busjahn
Friedrich C. Luft
Original Assignee
Florian Lang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Florian Lang filed Critical Florian Lang
Publication of CY1105566T1 publication Critical patent/CY1105566T1/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)

Abstract

Η εφεύρεση αφορά στην χρησιμοποίηση του άμεσου συσχετισμού μεταξύ της υπερέκφρασης ή της λειτουργικής μοριακής τροποποίησης ανθρωπίνων ομολόγων της οικογένειας sgk και της υπέρτασης για την ποσοτική διάγνωση μίας συγκεκριμένης μορφής της γενετικής προέλευσης υπέρτασης. Ιδιαιτέρως αφορά η εφεύρεση στην ανίχνευση μίας άμεσης σχέσης μεταξύ δύο διαφορετικών πολυμορφισμών επί μέρους νουκλεοτιδίων στο γονίδιο hsgk1 και της γενετικής προέλευσης προδιάθεσης για υπέρταση. Η εφεύρεση αφορά περαιτέρω στην διάθεση ενός διαγνωστικού κιτ που περιέχει αντισώματα ή πολυνουκλεοτίδια για την ανίχνευση του διαγνωστικού στόχου hsgk1, hsgk2 και hsgk3.
CY20061101052T 2001-03-21 2006-07-28 Ποσοτικη διαγνωστικη αναλυση της προδιαθεσης για υπερταση CY1105566T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10113876A DE10113876A1 (de) 2001-03-21 2001-03-21 Quantitative diagnostische Analyse der Hypertonie
EP02712954A EP1390531B1 (de) 2001-03-21 2002-03-21 Quantitative diagnostische analyse der prädisposition für hypertonie

Publications (1)

Publication Number Publication Date
CY1105566T1 true CY1105566T1 (el) 2010-07-28

Family

ID=7678460

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101052T CY1105566T1 (el) 2001-03-21 2006-07-28 Ποσοτικη διαγνωστικη αναλυση της προδιαθεσης για υπερταση

Country Status (18)

Country Link
US (1) US20060127892A1 (el)
EP (1) EP1390531B1 (el)
JP (1) JP2004528032A (el)
CN (1) CN1306040C (el)
AT (1) ATE331043T1 (el)
AU (1) AU2002244751B2 (el)
CA (1) CA2441314C (el)
CY (1) CY1105566T1 (el)
DE (2) DE10113876A1 (el)
DK (1) DK1390531T3 (el)
ES (1) ES2266463T3 (el)
HK (1) HK1063338A1 (el)
HU (1) HUP0303491A3 (el)
MX (1) MXPA03008522A (el)
PL (1) PL364387A1 (el)
PT (1) PT1390531E (el)
RU (1) RU2287160C2 (el)
WO (1) WO2002074987A2 (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1455815A4 (en) 2001-12-19 2006-11-02 Millennium Pharm Inc MEMBERS OF THE DIACYLGLYCEROL-ACYLTRANSFERASES FAMILY 2 (DGAT2) AND USES THEREOF
US6830911B2 (en) * 2002-02-08 2004-12-14 Applera Corporation Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
DE10305213A1 (de) * 2003-02-07 2004-08-26 Florian Prof. Dr.med. Lang Verwendung eines neuen Polymorphismus im hsgk1-Gen zur Diagnose der Hypertonie und Verwendung der sgk-Genfamilie zur Diagnose und Therapie des Long-Q/T-Syndroms
KR101032281B1 (ko) * 2003-03-03 2011-05-06 플로리안 랑 진단 및 치료 표적으로서의 ｓｇｋ１
DE10346913A1 (de) 2003-10-09 2005-05-04 Merck Patent Gmbh Acylhydrazonderivate
WO2007025792A1 (de) * 2005-09-02 2007-03-08 Florian Lang Verfahren zur diagnose von hypertonie
CN102654893A (zh) * 2011-03-04 2012-09-05 苏州卫生职业技术学院 分析高尿酸血症和高血压患病率关系的方法
WO2023114714A1 (en) * 2021-12-14 2023-06-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Sgk1 inhibitory compositions and methods

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19917990A1 (de) * 1999-04-20 2000-11-02 Florian Lang Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk

Also Published As

Publication number Publication date
WO2002074987A3 (de) 2003-12-04
US20060127892A1 (en) 2006-06-15
AU2002244751C1 (en) 2002-10-03
PL364387A1 (en) 2004-12-13
CA2441314A1 (en) 2002-09-26
CN1306040C (zh) 2007-03-21
HK1063338A1 (en) 2004-12-24
EP1390531A2 (de) 2004-02-25
EP1390531B1 (de) 2006-06-21
ES2266463T3 (es) 2007-03-01
WO2002074987A2 (de) 2002-09-26
MXPA03008522A (es) 2005-03-07
CA2441314C (en) 2011-11-08
RU2287160C2 (ru) 2006-11-10
DE10113876A1 (de) 2002-09-26
AU2002244751B2 (en) 2007-01-11
RU2003130071A (ru) 2005-04-10
HUP0303491A2 (hu) 2004-08-30
CN1503848A (zh) 2004-06-09
DE50207305D1 (de) 2006-08-03
DK1390531T3 (da) 2006-10-23
PT1390531E (pt) 2006-09-29
JP2004528032A (ja) 2004-09-16
ATE331043T1 (de) 2006-07-15
HUP0303491A3 (en) 2005-12-28

Similar Documents

Publication Publication Date Title
CY1105566T1 (el) Ποσοτικη διαγνωστικη αναλυση της προδιαθεσης για υπερταση
CY1123971T1 (el) Επισημασμενα νουκλεοτιδια
ATE167680T1 (de) Pteridin-nukleotidderivate als fluoreszierende sonden
EP1578952A4 (en) DIRECT SNP DETECTION WITH UNAMPLIFIED DNA
WO2002089657A3 (en) Diagnostic markers of acute coronary syndromes and methods of use thereof
AU2002303444A1 (en) Detection of microsatellite instability and its use in diagnosis of tumors
PT2332582E (pt) Activação de ace2 para o tratamento de doença cardíaca, pulmonar e renal e de hipertensão
EP1980629A3 (en) Identification of an erbb2 gene expression signature in breast cancers
BRPI0515794A (pt) processos para avaliar pacientes com leucemia mielóide aguda
ATE495434T1 (de) Nukleinsäuresequenzidentifikation
BR0314155A (pt) Métodos para diagnosticar câncer cervical
TR200402517T1 (tr) HBV ilaç direnci tespit metotları
MXPA05014220A (es) Genes regulados en cancer ovarico como objetivos de pronostico y terapeuticos.
WO2003063773A3 (en) Differentially-regulated prostate cancer genes
WO2003054166A3 (en) Nucleotide polymorphisms associated with osteoarthritis
BRPI0413825A (pt) detecção molecular multialélica de coronavìrus associado com sars
WO2004040312A3 (fr) Proceded de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
DK1366187T3 (da) Oligonukleotider til mærkning af oligonukleotidprober og proteiner
DK1095032T3 (da) Hidtil ukendte fluorescerende CYP2D-assayreagenser
ATE364616T1 (de) Nucleinsäuremolekül, kit und verwendung
EA200600012A1 (ru) Полиморфизм человеческого гена nbs1, полезный для диагностики наследственной предрасположенности к раку
ATE374260T1 (de) Asthma-assoziiertes gen
CY1114765T1 (el) Ενεργοποιηση ace2 για θεραπεια ασθενειας της καρδιας, του πνευμονα και του νεφρου και υπερτασης
WO2004048548A3 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2006021874A3 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of prostate cancer